BINYAMINA, Israel, Sept. 13, 2021 /PRNewswire/ — OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has published a study identifying a predictive proteomic signature for patient response to immune checkpoint inhibitor (ICI) therapy in non-small-cell lung carcinoma (NSCLC) patients. The signature was discovered using OncoHost’s first-of-its-kind, AI-based platform, PROphet®, and the study will be presented as a poster at the ESMO Virtual Congress 2021.

Read more here.